收入预测与决定接受哪些有风险合同是两回事，规划周期通常只产出前者，而业务需要后者来防止已签署成果风险导致毛利率侵蚀。 数字健康公司面临的问题版本并非通用版。成果风险签署速度快于公司能否承担的判断速度——12个月测量窗口对11个月销售周期——因此忽略有风险收入份额的答案会自信地出错。分析必须从参与率和毛利率而非收入开始。
收入预测与决定接受哪些有风险合同是两回事，规划周期通常只产出前者，而业务需要后者来防止已签署成果风险导致毛利率侵蚀。 数字健康公司面临的问题版本并非通用版。成果风险签署速度快于公司能否承担的判断速度——12个月测量窗口对11个月销售周期——因此忽略有风险收入份额的答案会自信地出错。分析必须从参与率和毛利率而非收入开始。
数字健康领域的规划通常从各团队列出可签署的额外有风险份额开始，把每成员每月数字汇总后发现超出12个月测量窗口在11个月销售周期下的承受能力，随后把每行按相同比例削减，以使公布的计划仍显示增长至340,000名注册成员且不拒绝任何合同。
顾问常被请来在纸面上都具增厚性的合同间强制选择，而真正限制在于放弃一份就意味着CEO或CFO必须告知付款方不会追求归属成果，这一承认会立即提高剩余账簿的标识流失风险，因此直到数字逼迫前都会回避。
聘请外部帮助的第二个更窄原因是：内部团队缺乏能力拉出五年参与率和毛利率按队列的历史，隔离每项有风险安排的每成员每月贡献，并展示保留或放弃特定合同同时业务继续销售的算术。
企业战略与转型汇集这些队列级边际并说明每个可能账簿的确切收入和流失后果，但无法强迫CEO或CFO接受任何单一付款方的损失；当约束是不愿承受损失而非缺少算术时，只有能揭示授权问题的推动者才会改变结果。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 上一次规划演示把所有现有有风险合同列为继续，没有一行显示终止或重新谈判参与率已产生负毛利率的队列。
✓ 滚动倡议追踪器仍包含前两个周期延续下来的相同三项提升参与率试点，且未越过设计阶段。
✓ 设定下一年每成员每月目标的财务模型仅在销售团队已承诺有风险收入目标之后完成，而非反过来。
通常会让情况更糟的做法。 聘请推动者来主持场外会议，而实际阻碍是CEO或CFO尚未决定必须拒绝哪些有风险份额，因此会议结束时更新的清单仍包含每份合同。
It is for you if you run or finance a digital health company and the last plan contained no decision to stop doing something. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 企业战略与转型, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
独立推动者主持场外会议并产出计划通常£8k–£30k。完整规划周期带分析的公司£60k–£200k。范围宽是因为两项工作不同：一项是推动，一项是证据。在比较报价前先决定缺哪一项，因为选错的廉价版仍是浪费。
短到权衡可见即可。有用的计划说明将在哪里取胜、将停止什么，以及必须成立的两三件事。典型规划文件的大部分篇幅是支持已做决定的证据，这些属于附录，无人需要读两遍。
方向定三年，资源承诺一年。三年财务细节在几乎所有业务中都是虚构精度，把它当作承诺会让计划脆弱。真正需要三年视角的部分是产能、资本和能力，因为这些无法在一年内改变。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית